• Safety, tolerability, relative bioavailability, pharmacokinetics, and pharmacodynamics of single and multiple doses of the novel oral bofanglutide in healthy Chinese participants

  Xiaohua Hao , Long Liu , Pu Li , Chunpu Lei , Yuanxu Tong , Junmin Dong , Xiaoyun Liu , Xiaoqiang Cheng , Jing Zhao , Xiao Min , Yining Zhang , Wei Chen

  博凡格鲁肽片 (GZR18)2型糖尿病

  查看文章

  发表时间

  2026-07-15

  开发阶段

  I期

  出版于

  Diabetes Research and Clinical Practice

• Weekly and biweekly treatment with bofanglutide versus semaglutide in Chinese patients with type 2 diabetes: A phase 2b randomized clinical trial

  Ming Liu, Zhifeng Cheng, Li Lu, Hanqing Cai, Jingyu Liu, Jinling Liu, Yueyue Zheng, Su Wang, Jing Zhao, Wei Yang, Tian Xie, Yue Li, Anshun He, Helena W Rodbard, Wei Chen

  博凡格鲁肽片 (GZR18)2型糖尿病

  查看文章

  发表时间

  2026-06-30

  开发阶段

  IIb期

  出版于

  Annals of Internal Medicine

• Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial

  Ming Liu, Xuhong Wang, Meizi Li, Enyue Yang, Aige Yang, Mingxia Yuan, Ruihua Dong, Guijun Qin, Ping Liu, Chengqian Li, Yu Cao, Jing Zhao, Liyuan Zhao, Wei Chen

  博凡格鲁肽 (GZR18)2型糖尿病

  查看文章

  发表时间

  2026-06-19

  开发阶段

  Ib/IIa期

  出版于

  Cell Reports Medicine

• GZR18, a GLP-1 Analog with Once-weekly or Bi-weekly Dosing for Body Weight Management: A Randomized, Placebo-Controlled, Phase 1b/2a Trial

  Linong Ji, Leili Gao, Ruihua Dong, Mingxia Yuan, Dong Zhao, Shuguang Pang, Jing Zhao, Liyuan Zhao, Wei Chen

  博凡格鲁肽 (GZR18)肥胖/超重

  查看文章

  发表时间

  2026-04-09

  开发阶段

  Ib/IIa期

  出版于

  Cell report medicine

• Once-weekly insulin GZR4 versus once-daily insulin degludec in Chinese people with type 2 diabetes: a multicenter, open-label, randomized, phase 2 trial

  Liming Chen, Xiaolin Dong, Qiumei Zhang, Huihui Wang, Hongyan Zhu , Zhifeng Cheng, Xiangqun Deng, Guang Wang , Jingyun Zhang, Xuerong Liu , Jing Zhao , Chunyue Hao, Tian Xie , Anshun He, Yue Li,Wei Chen

  Insulin ludefen (GZR4)2型糖尿病

  查看文章

  发表时间

  2026-03-14

  开发阶段

  II期

  出版于

  Metabolism

• Efficacy and safety of bofanglutide in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

  Linong Ji , Leili Gao , Junhang Tian , Ruihua Dong , Zhongtao Zhang , Hongyan Zhu, Jing Zhao , Liyuan Zhao , Anshun He , Tian Xie , Yue Li, Wei Chen

  博凡格鲁肽 (GZR18)肥胖/超重

  查看文章

  发表时间

  2026-02-27

  开发阶段

  IIb期

  出版于

  Signal Transduction and Targeted Therapy

• Pharmacokinetic Properties of Insulin GZR4 After Subcutaneous Administration in the Thigh, Abdomen or Upper Arm in Healthy Participants

  Long Liu, Junmin Dong, Yuanxu Tong, Pu Li,Xiaoyun Liu, Xiaoqiang Cheng, Yingjuan Zhang,Chunpu Lei, Fang Cheng, Jing Zhao, Wei Zhao, Wei Chen, Xiaohua Hao

  Insulin ludefen (GZR4)2型糖尿病

  查看文章

  发表时间

  2026-01-08

  开发阶段

  I期

  出版于

  Diabetes, Obesity and Metabolism

• A phase 1b, randomized, open-label study of once-weekly insulin GZR4 in patients with type 2 diabetes mellitus

  Xuhong Wang, Ye Hu, Chengyong Tang, Chenghu Huang , Fengxue Guo , Wei Chen

  Insulin ludefen (GZR4)2型糖尿病

  查看文章

  发表时间

  2025-12-18

  开发阶段

  Ib期

  出版于

  Diabetes Research and Clinical Practice

• GZR101, a Novel Premixed Insulin for the Treatment of Diabetes Mellitus

  Wei Chen, Cheng Cui, Wancai Xing, Yining Zhang, Anshun He, Yue Wang, Yan Huang, Nannan Zhai, Qimin Shi, Fangkai Xue, Yongchun Wang, Jun Zhang, Dongli Yu, Tian Xie, Yue Li, Zhong-Ru Gan

  GZR101糖尿病

  查看文章

  发表时间

  2025-06-18

  开发阶段

  临床前

  出版于

  Naunyn-schmiedebergs Archives Of Pharmacology

• The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects

  Yue Liu , Wei Chen , Xuemei He , Anshun He , Liyuan Zhao , Tian Xie , Yue Li , Jing Zhao , Allen Hunt , Aixin Shi , Zhong-Ru Gan

  博凡格鲁肽 (GZR18)2型糖尿病肥胖/超重

  查看文章

  发表时间

  2025-03-03

  开发阶段

  I期

  出版于

  Diabetes, Obesity and Metabolism

• Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4, a novel once-weekly basal insulin, in healthy participants: A randomized trial

  Chengyong Tang, Rui Su, Lei Wan, Mingxue Zhu, Junliang Pu, Chunyue Hao, Jing Zhao, Anshun He, Tian Xie, Yue Li , Wei Chen, Zhong-Ru Gan

  Insulin ludefen (GZR4)2型糖尿病

  查看文章

  发表时间

  2025-02-11

  开发阶段

  Ia期

  出版于

  Diabetes, Obesity and Metabolism

• A comparative evaluation of bioequivalence of Gan & Lee glargine U300 and Toujeo® in Chinese healthy male participants

  Xiaoli Li, Anshun He, Bingyan Liu, Rongfang Shan, Juan Zhu, Xiaoyue Li, Tian Xie, Yue Li, Mengmeng Chen, He Su, Chaoyang Zhang, Lufeng Li, Dongmei Cheng, Juan Chen, Ying Wang, Yue Su, Yuanyuan Xu, Zhuoran Li, Huan Zhou, Wei Chen, Yuanyuan Liu

  糖尿病甘精300

  查看文章

  发表时间

  2024-08-07

  开发阶段

  I期

  出版于

  Frontiers in Endocrinology

• Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment

  Elena A. Christofides, Andrzej Stankiewicz,Douglas Denham , Diego Bellido MD 4, Edward Franek, Samer Nakhle, Monika Łukaszewic,John Reed, Victoria Cózar-León,Christine Kosch Dipl-Med 10,Piotr Karaś, David Fitz-Patrick, Yehuda Handelsman,Mark Warren , Priscilla Hollander,David Huffman, Philip Raskin,Tamás Oroszlán, Michael Lillestol, Fernando Ovalle

  长秀霖1型糖尿病

  查看文章

  发表时间

  2024-06-12

  开发阶段

  III期

  出版于

  Endocrine Practice

• Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study

  Elena A Christofides, Orlando Puente, Paul Norwood, Douglas Denham, Hiralal Maheshwari, Michael Lillestol, Terence Hart, Samer Nakhle, Anurekha Chadha, David Fitz-Patrick, Danny Sugimoto, Joseph Soufer, Douglas Young, Mark Warren, David Huffman, John Reed, Harold Bays, Samir Arora, Barbara Rizzardi, Raymond Tidman, Marc Rendell, Kimball A Johnson

  长秀霖2型糖尿病

  查看文章

  发表时间

  2024-04-01

  开发阶段

  III期

  出版于

  Diabetes, Obesity and Metabolism

• Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulins

  Wei Chen, Jia Lu, Leona Plum-Mörschel, Grit Andersen, Eric Zijlstra, Anshun He, Tian Xie, Longling Li, Chunyue Hao, Zhongru Gan, Tim Heise

  长秀霖速秀霖锐秀霖糖尿病

  查看文章

  发表时间

  2023-09-21

  开发阶段

  I期

  出版于

  Diabetes, Obesity and Metabolism

• Current Status of Weekly Insulin Analogs and Their Pharmacokinetic/Pharmacodynamic Evaluation by the Euglycemic Clamp Technique

  Na An, Xuhong Wang, Anshun He, Wei ChenLei Yin, Zhenglin Yao, Yue Wang, Michelle Mazuranic

  Insulin ludefen (GZR4)糖尿病

  查看文章

  发表时间

  2023-07-13

  开发阶段

  综述

  出版于

  Clinical Pharmacology In Drug Development

• Investigational cyclin-dependent kinase 4/6 inhibitor GLR2007 demonstrates activity against isocitrate dehydrogenase wild-type glioblastoma and other solid tumors in mice xenograft models

  Lei Yin, Zhenglin Yao, Yue Wang, Michelle Mazuranic

  GLR2007

  查看文章

  发表时间

  2022-08-11

  开发阶段

  临床前

  出版于

  Frontiers in Oncology

• Comparative efficacy and safety of two insulin aspart formulations (Rapilin and NovoRapid) when combined with metformin, for patients with diabetes mellitus: a multicenter, randomized, open-label, controlled clinical trial

  Jun Yao, Xiaohui Guo, Li Sun, Ping Han, Xiaofeng Lv, Xiuzhen Zhang, Zhaohui Mo, Wenying Yang, Lihui Zhang, Zhanjian Wang, Lvyun Zhu, Quanmin Li, Tao Yang, Wenbo Wang, Yaoming Xue, Yongquan Shi, Juming Lu, Yongde Peng, Fan Zhang, Dewen Yan, Damei Wang, Xuefeng Yu

  锐秀霖糖尿病

  查看文章

  发表时间

  2022-07-22

  开发阶段

  III期

  出版于

  Current Medical Research and Opinion.

• GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models

  Man Zhang, Yining Zhang, Xiaohong Peng, Anshun He, Yue Wang, Ying Deng, Cheng Cui, Fangkai Xue, Bing Wei, Wancai Xing, Yuzhen Qian, Michelle Mazuranic, Wei Chen

  博凡格鲁肽 (GZR18)2型糖尿病肥胖/超重

  查看文章

  发表时间

  2022-06-16

  开发阶段

  临床前

  出版于

  European Journal of Pharmacology

暂无匹配的论文